Growth Metrics

BeOne Medicines (ONC) Short term Debt (2017 - 2025)

Historic Short term Debt for BeOne Medicines (ONC) over the last 10 years, with Q3 2025 value amounting to $813.3 million.

  • BeOne Medicines' Short term Debt fell 584.71% to $813.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $813.3 million, marking a year-over-year decrease of 584.71%. This contributed to the annual value of $851.5 million for FY2024, which is 2370.29% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Short term Debt is $813.3 million, which was down 584.71% from $808.4 million recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' Short term Debt peaked at $863.8 million during Q3 2024, and registered a low of $281.8 million during Q1 2023.
  • Moreover, its 5-year median value for Short term Debt was $441.3 million (2022), whereas its average is $565.0 million.
  • Per our database at Business Quant, BeOne Medicines' Short term Debt skyrocketed by 348510.36% in 2021 and then tumbled by 3082.55% in 2023.
  • Quarter analysis of 5 years shows BeOne Medicines' Short term Debt stood at $427.6 million in 2021, then tumbled by 30.33% to $297.9 million in 2022, then soared by 131.1% to $688.4 million in 2023, then increased by 23.7% to $851.5 million in 2024, then fell by 4.49% to $813.3 million in 2025.
  • Its Short term Debt stands at $813.3 million for Q3 2025, versus $808.4 million for Q2 2025 and $763.5 million for Q1 2025.